Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Axonics

Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot'

Cancer-focused biotech companies Ambrx and Harpoon snapped up a pair of takeover deals. AMAM stock and HARP stock soared.

Investors Business Daily

Small-Caps Are Poised to Climb, Baron Manager Says

Small-Caps Are Poised to Climb, Baron Manager Says

Randy Gwirtzman, co-manager of Baron Discovery Fund, shares his favorite small-cap stocks and industries.

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year

Biotech isn't the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.

Investors Business Daily

Medical Stock Shows Strength In A Weakening Market; Nears Buy Point

Medical device stock Axonics is near the buy point of a new basing pattern, which presents the potential for price gains ahead.

Investors Business Daily

Analyst Ratings for Axonics

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

Analyst Ratings For Axonics

Analyst Ratings For Axonics

Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter:

Axonics: Q4 Earnings Insights

Axonics: Q4 Earnings Insights

Axonics (NASDAQ:AXNX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by 8.11%, reporting an EPS of $-0.34 versus an estimate of $-0.37.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play